ClinicalTrials.gg
CompletedNCT07444762Updated Mar 6, 2026

Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421A

A Phase 3 interventional study of DW5421A and DW5421B Placebo in Primary Hypercholesterolemia and Mixed Dyslipidemia, sponsored by Daewon Pharmaceutical Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-03-06.

Primary conditionHypercholesterolemiaRegistry: DyslipidemiasReclassifiedWhy we changed it
Registry
Dyslipidemias — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypercholesterolemia
Why
  1. The study's listed conditions name Hypercholesterolemia, a narrower term within Dyslipidemias.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Daewon Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Apr 2025, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 81 studies in Hypercholesterolemia with a site in Korea, Republic of — 6 open to participants now, 11 under way, 5 of them phase 3. Hypercholesterolemia · Korea, Republic of.

Enrollment
42nd of 66
184 · median 251
Started
2025
with 4 others
Phase 3
35 of 81
1 open now
Registered
75th of 81
by date
Lead sponsor
3 of 81
Daewon Pharmaceutical Co., Ltd.

Among the 81 studies in Hypercholesterolemia with a site in Korea, Republic of, this one is the 42nd largest by enrollment of the 66 interventional ones that give a count, is one of 5 that started in 2025, is one of 35 in phase 3, and was the 75th registered.

Hypercholesterolemia

1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

6 of the 81 studies in Hypercholesterolemia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 58 Hypercholesterolemia studies recruiting now, 25 (43%) set no upper age limit and 21 (36%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Hypercholesterolemia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, active-controlled, parallel, phase III clinical trial to evaluate the efficacy and safety of combination therapy of DW5421A/DW5421B versus monotherapy of DW5421A in patients with primary hypercholesterolemia or mixed dyslipidemia.

Read the detailed description

The primary objective is to demonstrate the superiority of combination therapy of DW5421A/DW5421B over monotherapy of DW5421A by comparing the change in LDL-C at week 8 after administration. Approximately equal numbers of patients were randomized in a 1:1 ratio to receive combination therapy of DW5421A/DW5421B or monotherapy of DW5421A for 8 weeks. Efficacy and safety assessments were conducted at week 4 and week 8.

03

Conditions studied

  • Primary Hypercholesterolemia
  • Mixed Dyslipidemia

Browse trials for

04

In context

Hypercholesterolemia Reclassified

1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

This study's enrollment of 184 is above the median of 108 across 979 interventional studies indexed under Hypercholesterolemia.

Browse Hypercholesterolemia studies →

Lead sponsor

Daewon Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 7 are open to participants now.

Compared within Hypercholesterolemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dyslipidemias. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Subjects must meet all of the following criteria to be eligible for the study: [Screening]

  1. Male or female aged ≥19 years
  2. Subjects diagnosed with primary hypercholesterolemia or mixed dyslipidemia
  3. Subjects who satisfy both of the following criteria at Visit 1: (1) Triglyceride (TG) \< 400 mg/dL; (2) Low-density lipoprotein cholesterol (LDL-C) ≤ 250 mg/dL
  4. At Visit 1, for subjects who are receiving hypercholesterolemia treatment, those who, in the investigator's judgment, can medically and appropriately discontinue their existing hypercholesterolemia treatment for the duration of the clinical trial.
  5. Subjects who voluntarily provided written to participate in this clinical trial.

[Randomization]

  1. If currently receiving hypercholesterolemia treatment, subjects who have undergone a of at least 4 weeks prior to Visit 2.
  2. Subjects who have implemented TLC for at least 4 weeks prior to Visit 2 and have continued TLC through Visit 3.
  3. Subjects whose RIP IP compliance during the run-in period is between 70% and 130%.
  4. Subjects whose central laboratory test results at Visit 2 meet the criteria.

Exclusion criteria

Exclusion Criteria:

  • Subjects who meet any of the following conditions will not be eligible to participate in this clinical trial:

    1. Presence of any of the following medical histories or past surgical histories:

    <!-- -->

    1. Acute arterial disease-related history (as of Visit 1, within the 12-week period preceding the visit including: Unstable angina, myocardial infarction, (TIA), cerebrovascular disease, coronary artery bypass graft (CABG), or percutaneous coronary intervention (PCI)) Exception: Subjects whose events occurred more than 12 weeks before Visit 1, have been adjudicated as cured, or are in a stable state (ex: managed with a stable drug dosage for at least 12 weeks prior to Visit 1) may be eligible.
    2. or prior exposure to the product's active ingredients (pitavastatin, ezetimibe) or to any dyslipidemia-treating agents.
    3. History of fibromyalgia, myopathy, rhabdomyolysis, or other hereditary myopathies, or a family history of such conditions.
    4. Severe heart failure ( functional class III or IV).
    5. Any surgical or internal medical condition that could affect the absorption, distribution, metabolism, or excretion of the investigational drug (excluding uncomplicated appendectomy or hernia repair).
    6. A history of drug or alcohol abuse within 1 year prior to Visit 1.
    7. A history of (however, the following cases are eligible for participation):

      ① If at least 5 years have passed since completion of treatment for the tumor as of Visit 1, or if the subject is disease-free status.

      ② If at least 3 years have passed as of Visit 1 since complete excision of basal cell carcinoma or squamous cell carcinoma of the skin, curative resection of papillary thyroid carcinoma, or successful treatment of cervical carcinoma in situ.

    2. Subjects with the following comorbidities:

    1. Uncontrolled hypertension (SBP ≥ 180 mmHg or DBP ≥ 110 mmHg)
    2. Uncontrolled diabetes mellitus ( ≥ 9%)
    3. Uncontrolled thyroid dysfunction (TSH ≥ 1.5 × )
    4. Hepatic dysfunction ( or ALT ≥ 2 × ULN)
    5. Renal impairment ( \< 30 mL/min/1.73 m²)
    6. CK ≥ 2 × ULN
    7. Biliary obstruction or cholestasis
    8. Moderate hepatic disease or active liver disease
    9. Hypothyroidism
    10. Uncontrolled arrhythmia, as determined by the investigator
    11. Interstitial lung disease 3. Subjects who are administrating or are expected to administer concomitant medications prohibited by this clinical trial.

    4. Subjects with chronic conditions requiring continuous use of systemic or .

    5. Subjects with secondary dyslipidemia due to conditions such as Cushing's syndrome, hypothyroidism, obstructive liver disease, or nephrotic syndrome.

    6. and pregnancy:

    1. Pregnant or breastfeeding women, or those planning to become pregnant or breastfeed during the clinical trial period.
    2. Women of and men who do not agree to use appropriate contraception as specified in the protocol during the clinical trial period.

    7. Subjects who have participated in another clinical trial and administered investigational product (or undergone an investigational medical device procedure) within 12 weeks prior to screening (however, enrollment may be permitted if participation was limited to an observational or retrospective study and, in the investigator's judgment, does not affect the efficacy or safety of this clinical trial).

    8. Subjects deemed unsuitable for participation in this clinical trial at the investigator's discretion.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
184 participants (actual)

Study arms

  • Experimental
    Combination Therapy of DW5421A/DW5421B

    Combination Therapy of DW5421A/DW5421B

    Drug: DW5421A · Drug: DW5421B

  • Active comparator
    Monotherapy of DW5421A

    Monotherapy of DW5421A

    Drug: DW5421A · Drug: DW5421B Placebo

Interventions

  • DrugDW5421A

    IP is administered orally once daily at a consistent time each day, with or without food.

  • DrugDW5421B Placebo

    IP is administered orally once daily at a consistent time each day, with or without food.

  • DrugDW5421B

    IP is administered orally once daily at a consistent time each day, with or without food.

07

What researchers measure

Primary outcomes

  1. LDL-C change rate

    LDL-C change rate at week 8 compared with baseline

    Time frame: week 8

08

Study locations

1 site
  • Korea University Anam Hospital
    Seoul, 02841, South Korea
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Oct 2025, 6 months.

Of 123 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 6 months is below that.

Counting every sponsor, half of 126 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 3, 2026
StartActual
Apr 21, 2025
Primary completionActual
Oct 21, 2025
CompletionActual
Oct 21, 2025
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07444762
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Apr 21, 2025
Primary completion
Oct 21, 2025
Completion
Oct 21, 2025
Last update
Mar 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion